Company overview
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Daily valuation snapshot
These values are from the stored daily market snapshot dated 2026-10-08. They are not a live quote.
| Daily close (USD) | $1.66 |
| Market capitalization (USD) | $346,818,722.06 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.56 |
No matching rows. Clear the filter to see all records.
Continue the research
Read public ownership disclosures separately from company fundamentals. Test a strategy against dated historical observations before evaluating its assumptions; a past result is not a live trading outcome.